Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice
暂无分享,去创建一个
G. Van den Berghe | F. Nevens | P. Bedossa | D. Cassiman | I. Vanhorebeek | B. Cammue | J. van Pelt | K. Thevissen | Ingrid Vander Elst | Pieter Spincemaille | Petra Windmolders | J. Verbeek | S. van der Merwe
[1] A. Ore,et al. Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease , 2018, Medicina.
[2] L. Ramalho,et al. Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome , 2017, Diabetology & Metabolic Syndrome.
[3] D. Cassiman,et al. Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis , 2016, Current protocols in mouse biology.
[4] D. Jump,et al. Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible? , 2016, PloS one.
[5] S. Friedman,et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.
[6] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[7] J. Auwerx,et al. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis , 2014, Gut.
[8] Aijaz Ahmed,et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.
[9] F. Nevens,et al. P245 ROUX-EN-Y GASTRIC BYPASS ATTENUATES HEPATIC MITOCHONDRIAL DYSFUNCTION IN MICE WITH NONALCOHOLIC STEATOHEPATITIS , 2014 .
[10] V. Arroyo,et al. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity‐induced steatohepatitis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] 平田 匠. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease : fatty liver protection trial by telmisartan or losartan study (FANTASY) , 2014 .
[12] M. Muiesan,et al. Nutraceuticals and dyslipidaemia: Beyond the common therapeutics , 2014 .
[13] J. Rieusset,et al. Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] V. Ratziu,et al. Pharmacological agents for NASH , 2013, Nature Reviews Gastroenterology &Hepatology.
[15] R. Rector,et al. The role of angiotensin II in nonalcoholic steatohepatitis , 2013, Molecular and Cellular Endocrinology.
[16] Luca Valenti,et al. Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment , 2013, Current pharmaceutical design.
[17] R. Dalle Grave,et al. The role of lifestyle change in the prevention and treatment of NAFLD. , 2013, Current pharmaceutical design.
[18] M. Yeh,et al. Dietary modification dampens liver inflammation and fibrosis in obesity‐related fatty liver disease , 2013, Obesity.
[19] F. Nevens,et al. Treatment of non-alcoholic fatty liver disease: can we already face the epidemic? , 2013, Acta gastro-enterologica Belgica.
[20] R. Morishita,et al. Potential effect of angiotensin II receptor blockade in adipose tissue and bone. , 2013, Current pharmaceutical design.
[21] Simona Calugi,et al. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. , 2013, Journal of hepatology.
[22] L. Afman,et al. Phenotyping the effect of diet on non-alcoholic fatty liver disease. , 2012, Journal of hepatology.
[23] Joan Tordjman,et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.
[24] Christian Thoma,et al. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. , 2012, Journal of hepatology.
[25] D. Schuppan,et al. Anti-fibrotic therapy: lost in translation? , 2012, Journal of hepatology.
[26] J. Heimbach,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.
[27] N. Lundbom,et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. , 2011, The American journal of clinical nutrition.
[28] N. Chalasani,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.
[29] R. Morishita,et al. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. , 2011, Current vascular pharmacology.
[30] Jan Gunst,et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. , 2011, The Journal of clinical endocrinology and metabolism.
[31] H. Tilg,et al. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.
[32] H. Yki-Järvinen. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data , 2010, Current opinion in clinical nutrition and metabolic care.
[33] G. Musso,et al. A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.
[34] E. Jackvony,et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.
[35] H. Yoshiji,et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat , 2009, BMC Research Notes.
[36] G. Bjørkøy,et al. Monitoring autophagic degradation of p62/SQSTM1. , 2009, Methods in enzymology.
[37] E. Georgescu. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option? , 2008, Advances in therapy.
[38] D. Cassiman,et al. NASH may be trash , 2008, Gut.
[39] J. Miquel,et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis , 2007, Journal of gastroenterology and hepatology.
[40] E. Georgescu,et al. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. , 2007, Journal of gastrointestinal and liver diseases : JGLD.
[41] G. Bergström,et al. Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE−/− mice , 2006, Journal of hypertension.
[42] G. Bedogni,et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.
[43] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[44] Y. Tokusashi,et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis , 2004, Hepatology.
[45] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[46] V. Paradis,et al. Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.
[47] G. Marchesini,et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.